Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene
expression changes of various immune cell and tumor markers in cutaneous metastases treated
with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune
checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe
the adverse events associated with DPCP when administered topically twice weekly for 12 weeks
in combination with PD-1 or PD-L1 ICI.